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Pancreatic beta-cells, which secrete the hormone insulin, are the key arbiters of glucose homeostasis. Defective beta-cell numbers
and/or function underlie essentially all major forms of diabetes and must be restored if diabetes is to be cured. Thus, the
identification of the molecular regulators of beta-cell mass and a better understanding of the processes of beta-cell diﬀerentiation
and proliferation may provide further insight for the development of new therapeutic targets for diabetes. This review will focus
on the principal hormones and nutrients, as well as downstream signalling pathways regulating beta-cell mass in the adult.
Furthermore, we will also address more recently appreciated regulators of beta-cell mass, such as microRNAs.
1. Introduction
The endocrine cells of the pancreas, located in the islets of
Langerhans, are responsible for blood glucose homeostasis,
secreting hormones with diﬀering and even opposing eﬀects
on blood glucose disposal. Beta-cells, the most numerous
islet cells, secrete the hormone insulin which reduces blood
glucose levels by increasing peripheral uptake of glucose and
by suppressing release of glucose from the liver. Conversely,
islet alpha-cells secrete the hormone glucagon which can
increase blood glucose levels. Glucagon mainly acts on the
liver where it promotes glycogenolysis, releasing glucose
from breakdown of glycogen stores and gluconeogenesis.
Optimal control of blood glucose levels depends on delicate
changes in insulin production and secretion by the pancre-
atic beta-cells and on their capacity for large increases in
secretion after meals, requiring large stores of insulin. It is of
critical importance that islets maintain an adequate beta-cell
mass in response to various changes.
Recent evidence has revealed that beta-cell replication
plays a central role in maintaining adult beta-cell mass [1].
In addition, rates of beta-cell proliferation change dynam-
ically according to metabolic demand throughout life [2].
However, replication of pre-existing beta-cells is not the only
available mechanism for generating new beta-cells. In fact, a
reasonable body of evidence supports the existence of four
other potentially important contributors to adult beta-cell
mass regulation: (i) diﬀerentiation from stem cells precur-
sors, (ii) transdiﬀerentiation from a non-beta-cell diﬀer-
entiated precursor, (iii) whole islet neogenesis on the plus
side and apoptosis on the negative, and (iv) changes in
beta-cell size [3, 4]. However, the relative contribution of
these processes in maintaining and expanding beta-cell mass
is at present not well defined and varies between species [5–
7]. During adult life, the beta-cell mass may have to adapt
in the face of increased demands due to increases in body
mass, pregnancy, or even loss of insulin sensitivity of peri-
pheral tissues. If such compensatory adaptation is inade-
quate, then glucose homeostasis will be compromised and
result in chronically elevated blood glucose, or diabetes [8,
9].
It is well known that beta-cells proliferate extensively dur-
ing late embryonic development, but the rate of replication
slows during postnatal life. During adult life, beta-cell pro-
liferation is detected between 0.5% and 2% [10] gradually
declining with age [11]. Remarkably, this low rate of baseline
proliferation can be increased significantly in response to
pregnancy or obesity and is regarded as an adaptive mecha-
nism in response to increasing systemic insulin demand.
Although important roles of insulin [12] and glucose
[13] in beta-cell compensation have been suggested, the
mechanism underlying this process is not well understood.
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In recent years, various groups have identified microR-
NAs (miRNAs) small molecules of noncoding RNA that are
able to regulate protein expression that contribute to beta-
cell dysfunction and diabetes onset [14–18]. However, the
role of these miRNAs is not yet fully understood.
Type 2 diabetes (T2D) is characterized by hyperglycae-
mia resulting from impaired insulin secretion and/or im-
paired insulin action in peripheral tissues [19]. T2D consti-
tutes one of the greatest pandemics of our time, with 220
million people currently diagnosed [20], and 439 million
people expected to be aﬀected by 2030 [21]. Importantly,
there is substantial evidence that beta-cell dysfunction plays
a major role in the pathology of T2D. For this reason, great
eﬀorts are being made in order to develop new therapeutic
strategies, such as beta-cell replacement or regenerative
medicine.
However, despite progress, most diabetic patients will
still die prematurely as a direct result of their disease, its
complications, or sometimes even its treatments. In fact,
although one may hope that GLP-1 analogues and improved
lifestyle may eventually translate into a slowing of T2D pro-
gress, clinical trials data have been generally disappointing
and confirm that the disease continues to progress [22–25].
To date, no eﬀective treatments for T1D based on slowing
or reversing the natural history of the disease exist. Thus we
must rely on treatments that can maintain or restore blood
glucose levels, and evidences that disease progression can be
significantly arrested are scanty. Thus, all T1D and over time
most T2D patients will require exogenous insulin (or in rare
cases an islet transplant). It is not all negative, and short-term
benefits (usually progression from prediabetes to overt dia-
betes) have been reported in small studies for metformin and
acarbose with the common factor likely to be weight loss. The
similar success of supervised weight loss programs supports
this view. Trials with the PPARg ligand rosiglitazone have also
suggested that the progression of T2Dmay be retarded, but as
the drug has been withdrawn, due to an increased risk of car-
diovascular disease, this remains interesting rather than clin-
ically useful. In the largest study of T2D to date (UKPDS-UK
Prospective Diabetes Study (UKPDS)Group), treatments did
not slow progression of patients to additional drugs in order
to maintain blood glucose levels at target levels [26].
Furthermore, beta-cells from donor pancreases are in
such short supply that transplants can be provided only to a
limited number of patients. Ultimately, to cure diabetes, mis-
sing beta-cells that must be replaced, and in practical terms
this would need to be done from within or a limitless source
of beta-like cells must be developed for transplants. One way
forward is to “create” beta-cells from alternative cell sources
(neogenesis, transdiﬀerentiation, stem cells, etc.). Such an
approach requires further knowledge of the mechanisms that
regulate pancreatic beta-cell mass.
This review briefly outlines current knowledge of signif-
icant factors/nutrients regulating beta-cells mass, and their
signal transduction pathways, with greater focus on postnatal
regulation and the role of a new class of beta-cell mass regu-
lators: the microRNAs.
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Figure 1: Beta-cell mass equilibrium. Beta-cell proliferation,
neogenesis, and hypertrophy (enlarged cell size) increase beta-cell
mass, while apoptosis and atrophy (reduced cell size) decrease beta-
cell mass.
2. Postnatal Beta-Cell Regulation
How Do Beta-Cells Maintain Their Normal Mass? Beta-cell
mass is increased by neogenesis (diﬀerentiation from beta-
cell precursor cells), proliferation, and cell hypertrophy (in-
creased cell size) and is decreased by beta-cell death, primar-
ily through apoptosis, and beta-cell atrophy (decreased cell
size, Figure 1). Several studies have revealed that the primary
mechanism by which new beta-cells arise during adulthood
is through proliferation of existing beta-cells rather than
neogenesis [7, 27]. Thus, organisms born with reduced beta-
cell mass have fewer beta-cells available to enter the cell cycle
later in life. Under normal circumstances during adulthood,
beta-cells are a slowly renewing population, with steady low
levels of proliferation and apoptosis. However, beta-cell mass
continuously expands over the lifespan of an organism [28],
likely due to age-related increases in body weight and insulin
resistance. A large number of hormones and nutrients have
been shown to aﬀect beta-cell mass, as extensively reviewed
by Nielsen et al. [29]. As a result, the number of molecular
pathways that have been implicated in beta mass regulation is
also large. Many studies have employed animal models, and
it is important to note that significant diﬀerences between
species have been observed [30].
2.1. Regulation of Beta-Cell Mass by Hormones, Growth
Factors, and other Factors. Beta-cell mass regulation is
modulated by various environmental factors and nutrients
including glucose, insulin, amino acids, fatty acids, and
various other growth factors/hormones, such as IGF-I,
IGF-II, glucagon-like peptide-1 (GLP-1) 1, glucagon, gas-
troinhibitory peptide (GIP), somatostatin (SST), HGF and
betacellulin, gastrin, cholecystokinin (CCK), growth hor-
mone (GH), prolactin (PRL), placental lactogen (PL),
and leptin, amongst others (Table 1). These growth fac-
tors and nutrients can aﬀect a variety of beta-cell func-
tions—suppress/stimulate beta-cell replication, survival,
mass expansion, and diﬀerentiation through diﬀerent intra-
cellular pathways discussed later.
Glucose. Glucose is thought to be the most important
determinant of beta-cell mass equilibrium [31–36]. Glucose
is not only the pathological hallmark of diabetes, but it is also
a potential contributor to further decline in beta-cell mass
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Table 1: Hormones, growth factors, and other factors regulating beta-cell mass.
Inhibitors Stimulators
Metabolites Glucose, FFA Glucose, FFA, amino acids
Cytokines IL-1, IFN-g, TNF-a, leptin GH, PRL, PL
Growth factor family HGF IGF-I, IGF-II, insulin, TGF-a, betacellulin, HB-EGF, aFGF, VEGF, PDGF, HGF
Placental hormones placental lactogen, prolactin
Glucagon family GLP-1, GIP, glucagon
Somatostatin family Somatostatin
CGRP family IAPP/amylin
Gastrin family Gastrin, CCK
TGF-b family TGF-b, follistatin Activin A
Neurotrophins NGF, NT-3
Neurotransmitters (Nor)epinephrine Acetylcholine
Lectins Reg/INGAP/PSP/PTP
Adhesion molecules Integrin a6b1, Cx43, Cx36
Drugs Diazoxide Nicotinamide, SU
Toxins Streptozotocin, alloxan
Modified from Nielsen et al. [29]. aFGF, acidic fibroblast growth factor; CCK, cholecystokinin; Cx. Connexin; HB-EGF, heparin-binding EGF-like protein;
HGF, hepatocyte growth factor/scatter factor; IAPP, islet amyloid polypeptide; IFN, interferon; IL, interleukin; INGAP, islet neogenesis- associated peptide;
NGF, nerve growth factor; NT-3, neurotrophin-3; PDGF, platelet-derived growth factor; PSP, pancreatic stone protein; PTP, pancreatic thread protein; SU,
sulfonylurea; TGF, transforming growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
through what has been termed glucotoxicity. Thus, in the
face of evolving demand for insulin, if adaptation (functional
or numeric) fails, then blood glucose levels rise, sequentially
resulting in IGT and then T2D. Once glucose levels exceed
the safe threshold, then further beta-cell death will likely arise
[37].
It has been reported that hyperglycaemia for a short time
in rats induces beta-cells to enter the cell cycle accompanied
by∼50% increase in beta-cell number by neogenesis [33, 38]
and suppression of beta-cell apoptosis [33, 36]. In another
study using prolonged periods of glucose infusion, an in-
crease of beta-cell mass was also reported, although the orig-
in of these cells has been disputed. While some authors
describe proliferation of new beta-cells formed by neogenesis
of precursor cells [36], other groups report an increase in
beta-cell replication and hypertrophy as well as neogenesis,
leading to sustained eﬀects on beta-cell mass even after
glucose infusion is stopped [35, 39].
To support the mitogen eﬀect of glucose on beta-cells,
Porat and colleagues demonstrated in an animal model an
increased replication rate of beta-cells correlated with an
increased blood glucose level. Moreover, this eﬀect wasmedi-
ated by a specific enzyme involved in glucose metabolism
(glycolysis) in beta-cells, glucokinase (GCK). In fact, it was
demonstrated that GCK has a key role in beta-cell prolifera-
tion through membrane depolarization [40].
In addition, glucose has been shown to promote beta-
cell survival by suppressing a constitutive apoptotic program
in vitro [41]. Moreover, it was reported that mild hyper-
glycaemia can aﬀect beta-cell phenotype [37] with a pro-
gressive loss of beta-cell diﬀerentiation markers (Pdx-1,
BETA2/NeuroD, NKX6.1, and HNF-1β) and genes involved
in glucose sensing (GLUT-2 and glucokinase) [37, 42]. On
the other hand, some genes that are normally suppressed
in beta-cells (e.g., c-Myc and its gene target, lactate dehy-
drogenase-A) are increased. This proapoptotic eﬀect of
glucose may also involve altered calcium homeostasis [43],
activation of caspases by cytokines, such as IL-1β which is
secreted by human islets in the presence of high glucose
and leads to beta-cell apoptosis [44] or Fas-Fas-Ligand in-
teractions [44], reactive oxygen species [45], and c-Myc [46,
47]. Intriguingly, c-Myc has been shown to trigger apoptosis
through all of these pathways in other systems, including in
particular the activation of some caspases (caspase 8 and 9),
Fas-Fas-Ligand signalling, and reactive oxygen species
(reviewed in [48]).
Therefore, paradoxically, it appears that glucose may
have both an inhibitory and stimulating eﬀect on beta-cell
apoptosis. However, it appears that both the level and dura-
tion of hyperglycaemia are crucial in determining the fate
of the beta-cell. For example, prolonged hyperglycaemia ap-
pears to have a proapoptotic eﬀect, a process referred to as
glucose toxicity. Chronic hyperglycemia may thus be inju-
rious to beta-cells and contribute to the development of
T2D [49]. Increased beta-cell apoptosis and reduced beta-
cell mass have been observed in humans with T2D also,
in keeping with the preclinical data in [6, 50–53]. This
diﬀerence in beta-cell mass between T2D patients and
matched controls is particularly evident when those are
matched for obesity (obese patients without T2D have
increased beta-cell mass compared to lean controls).
Insulin. The eﬀect of insulin on beta-cell mass has not been
completely clarified. Various authors have shown in various
in vivo studies that insulin alone can stimulate beta-cell mass,
whereas other authors have found that it promotes growth
only in the presence of hyperglycaemia [34, 36, 54–56].
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In a physiological condition, it seems reasonable that
during a period of increased insulin demand, insulin itself
could stimulate beta-cell growth, creating a positive feedback
loop. Further studies have suggested a positive role of insulin
in cell regeneration [57, 58].
Genetically altered mice in which the insulin receptor
was knocked out exhibited a decreased beta-cell mass in
adults and diabetes onset [59]. Insulin resistance, leading to
hyperinsulinemia, stimulates an increase in beta-cell mass.
In contrast, as previously described [60, 61], insulin can
also impose negative eﬀect on beta-cell mass and/or prolife-
ration. For example, rats with insulinomas resulting in hy-
perinsulinemia and hypoglycaemia were found to have
smaller beta-cells, as well as reduced beta-cell numbers (in
the islets without tumour), suggesting that a “sensor”mecha-
nisms exist that can co-ordinate beta-cell mass across islets
and possibly even distal grafts [62]. Increased rates of beta-
cell apoptosis were evident [60, 61], but interestingly, beta-
cell mass regenerated within days of tumour excision [63].
This demonstrates that excess insulin with a negative feed-
back is able to inhibit beta-cell growth.
These observations indicate that insulin can control beta-
cell population dynamics, although the mechanism is still
unclear.
Free Fatty Acids. Another proposed stimulus for beta-cell
mass regulation has been free fatty acids (FFAs). It is well
documented that chronic high levels of FFAs, which are often
accompanied by obesity, contributes to the pathophysiology
of insulin resistance and T2D [64, 65].
It is reported that acute FFA exposure stimulates insulin
secretion, while prolonged FFA exposure decreases glucose-
stimulated insulin secretion [66, 67] and induces insulin
resistance and beta-cell dysfunction in both animal models
[68] and humans [69–72].
Animal studies have been conflicting with some arguing
that FFAs have a positive trophic eﬀect on beta-cells, whilst
others suggest the contrary. However, precise molecular
mechanisms linking FFA to beta-cell dysfunction have yet to
be fully elucidated.
It was reported that a prolonged in vitro exposure of iso-
lated islets or insulin-secreting cell lines to elevated levels of
fatty acids is associated with inhibition of glucose-induced
insulin secretion [67, 73, 74], impairment of insulin gene
expression [75–78], and induction of cell death by apoptosis
both in vitro [79–88] and in vivo studies [80].
Importantly, in vitro [76, 88, 89] and in vivo [90, 91] stud-
ies have provided evidence that lipotoxicity only occurs in the
presence of concomitantly elevated glucose levels. A num-
ber of studies have shown that fatty acids can induce beta-
cell death by apoptosis in the presence of high glucose [88].
In vitro, saturated fatty acids induce beta-cell apoptosis [82,
86, 88], whereas unsaturated fatty acids are usually protective
[81, 82, 88].
Recently, it was observed by various authors that oxi-
dative stress is implicated in the pathogenesis of beta-cell
dysfunction induced by FFAs. It has been suggested that
increased reactive oxygen species (ROS) levels are the
important trigger for beta-cell dysfunction. Under diabetic
conditions, ROS is increased in many tissues and organs and
cause various forms of tissue damage in patients with dia-
betes. It is considered that enhanced ROS generation may act
as a link between FFA and beta-cell dysfunction [92].
Glucagon-Like Peptide-1. Glucagon-like peptide-1 (GLP-1) is
produced and secreted in response to fat and glucose from
intestinal L-cells, located in the distal ileum and colon.
Preclinical studies reveal potential benefits of GLP-1 re-
ceptor agonist treatment in individuals with T2D, which in-
clude the promotion of beta-cell proliferation [93] and re-
duced beta-cell apoptosis [94]. These preclinical results in-
dicate that GLP-1 could be beneficial in treating patients with
T2D.
However, the role of endogenous GLP-1 in stimulating
beta-cell proliferation is less clear. Data regarding the regen-
erative role of GLP-1 and related agonists are controversial.
However, there is strong evidence to suggest that GLP-1
receptor activation can protect beta-cells from apoptosis [94–
97] and equally convincing evidence of a beta-cell mitogenic
eﬀect of GLP-1 [93, 94, 98, 99].
It was reported that exogenous GLP-1 treatment enhan-
ces beta-cell replication in normoglycaemic rats [100] and
mice [101–105].
However, while there are reports of GLP-1-mediated islet
neogenesis [98, 106–109], recent statements by researchers
examining the in vivo eﬀects of GLP-1 call into question a
neogenic response [110–112].
GLP-1 treatment stimulates beta-cell replication in mul-
tiple rodent models of obesity-induced diabetes, including
both intact [113, 114] and defective leptin signalling [94,
115–117] models. In addition, some authors have demon-
strated that exogenous GLP-1 treatment promotes beta-cell
replication in models of beta-cell regeneration and obesity-
induced diabetes [118, 119].
Moreover, GLP-1 prevents beta-cell death inmousemod-
els of beta-cell loss, in particular, in both unstressed mice
[102] and in streptozotocin-induced beta-cell toxicity [95,
120]. In summary, exogenous GLP-1 treatment stimulates
beta-cell proliferation in multiple rodent species and models
of beta-cell mitogenesis. Reports of human beta-cell prolifer-
ation are, however, sparse. Data to support a role for endo-
genous GLP-1 signalling in beta-cell proliferation are less
clear.
Glucose-Dependent Insulinotropic Polypeptide. Glucose-de-
pendent insulinotropic polypeptide (GIP) is a gut hormone sy-
nthesized and secreted from intestinal K-cells, which reside
in the duodenum and jejunum.
It was previously reported that if GIP promotes beta-cell
proliferation during obesity, then GIP inhibition should re-
duce beta-cell mass [121].
However, it is unclear whether the primary eﬀect of GIP
antagonism is on the adipocyte or the beta-cell. Few studies
implicate GIP in in vivo beta-cell proliferation [119, 122].
However, one report demonstrated that GIP treatment
increases islet size and number in the Leptin ob/ob mouse
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[123]. The latter study did not discriminate between beta-
cell proliferation, apoptosis, or islet neogenesis. In a human
patient, elevated fasting plasma GIP correlated with islet cell
hyperplasia [124]. Despite the limited in vivo evidence, in
vitro experiments demonstrate that GIP enhances beta-cell
mitogenesis [125–128].
Furthermore, the role of GIP in the reduction of beta-cell
apoptosis in vivo is more clearly defined than its role in beta-
cell proliferation.
Various studies have also demonstrated that exogenous
GIP treatment prevents beta-cell apoptosis during severe
obesity [123, 129] and streptozotocin-induced diabetes [120,
129].
Insulin-Like Growth Factor I and II. The role of insulin-like
growth factor I (IGF-I) and insulin-like growth factor II (IGF-
II) in beta-cell mass regulation has long been accepted [130–
132].
IGF-I has been shown to increase the number of re-
plicating beta-cells in rodent islets by up to 6% of the islet
cell population [133–135] and to induce diﬀerentiated panc-
reatic beta-cell growth [133]. However, IGF-I appears only
to be eﬀective at inducing beta-cell proliferation under phy-
siologically relevant glucose concentration range: 6mM to
18mM [136]. Thus, IGF-I potentiates the mitogenic eﬀect
of glucose on beta-cell proliferation.
Interestingly, overexpression of IGF-I in beta-cells is asso-
ciated with increased beta-cell proliferation, but not mass
[137]. In contrast, transgenic mice overexpressing IGF-II ex-
hibit an increase in beta-cell mass due to augmented pro-
liferation [138]. Taken together, there is clear evidence that
the IGF molecules are important factors in beta-cell prolifer-
ation and mass.
Seemingly paradoxically, beta-cell-specific IGF-I knock-
out mice showed a delayed onset of T2D induced by a high-
fat diet, accompanied by enlarged pancreatic islets, increased
insulin mRNA levels, and preserved sensitivity to insulin
[139]. This is likely due to secondary increases in insulin and
others.Moreover, given the dominant role of circulating IGFs
on tissue mass homeostasis in other systems, the significance
of this is uncertain. Concerning IGF-II, it has been reported
that mice overexpressing this hormone display an increase
in beta-cell mass, hyperinsulinemia, and increased glucose-
stimulated insulin secretion [140]. These results suggest that
IGF-II may have some potential as an islet growth factor.
Cholecystokinin. Cholecystokinin (CCK) is able to stimulate
beta-cell proliferation in vivo, as reported by diﬀerent aut-
hors. In fact, various studies have demonstrated that the ad-
ministration of CCK-8 after streptozotocin treatment in rats
expands beta-cell mass via proliferation, in association with
fasting plasma insulin increasing, and fasting plasma glucose
reduction [141].
At the same time, it was reported that CCK enhances rat
beta-cell proliferation ex vivo. In fact, neonatal rat beta-cells
proliferate in culture after CCK-8 treatment [142]. Similarly,
in a rat model, loss of CCK resulted in decreased islet size
and reduced beta-cell mass through increased beta-cell death
[143]. However, overexpression of Cck in mouse and human
islets has no eﬀect on replication [143].
Parathyroid Hormone-Related Protein. A recent study has
demonstrated that acute and systemic administration of
the first 36 amino acids of parathyroid hormone-related
protein (PTHrP (1–36)) in rodents can stimulate beta-cell
proliferation and enhance beta-cell mass in vivo, without
negatively aﬀecting beta-cell function or survival [144]. Pre-
vious studies have demonstrated that RIP-PTHrP transgenic
mice producing the full-length PTHrP (1–139) in beta-cells
show an increase in beta-cell mass, proliferation and islet
number, and improvement of glucose homeostasis [145–
147]. In addition, in vitro studies (in rodent insulinoma cell
lines and primary human beta-cells) have shown that PTHrP
(1–36) is suﬃcient to enhance not only proliferation, but
also function, increasing insulin mRNA and protein, and
augmenting glucose-stimulated insulin secretion [148–150].
However, it is notable that PTHrP knockout mice have
normal beta-cell mass as compared to controls, suggesting
that PTHrP may not be crucial for normal beta-cell mass in
vivo. However, the explanation of this result should be found
on the possibility that the PTHrP was absent in islets but
it could be produced in other islet cell types, resulting in a
paracrine compensatory mechanism [151].
These findings suggest that PTHrP may provide a
possible target for gene therapeutic strategies designed to
increase beta-cell mass and function.
Ghrelin. Ghrelin is a stomach-derived hormone involved in
glucose metabolism and has been shown to regulate cellular
diﬀerentiation and proliferation in various systems. In beta-
cells, ghrelin treatment has been shown to increase expres-
sion of insulin and PDX1, as well as beta-cell replication in
a diabetes model [152]. This suggests a potential to increase
beta-cell mass and function.
Moreover, it has been recently reported that both acy-
lated- and unacylated-ghrelin can on the one hand promote
cell proliferation while on the other inhibit apoptosis of beta-
cells, including human pancreatic islets induced by serum
starvation and/or cytokine’s stimulation [153, 154].
Menin. Menin is a tumour suppressor encoded by the Men1
gene. Mice with heterozygous deletion for Men1 develop
pancreatic hyperplasia [155] that coincides with hyperin-
sulinemia and hypoglycaemia [156], with an increased islet
cell growth through a progressive reduction in expression of
some cell growth suppressors, such as p18 and p27 [157].
It was reported that the regulation of p18 and p27 by men-
in is through histone methylation [158, 159]. Moreover, mu-
tation of Men1 can induce acceleration in S-phase entry and
consequently an enhancement of cell proliferation in pan-
creatic islets [160]. Recently, it has been reported that menin
is also able to increase caspase-8 expression [161] and that
caspase-8 is critical for the maintenance of beta-cell mass
under physiological conditions [162].
More recently, menin has been demonstrated to play an
important role during pregnancy, but this will be discussed
below.
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Leptin. Leptin is one of the most important cytokines prod-
uced by the ob gene and secreted by adipose tissue, and it
plays an important role in controlling food intake/satiety and
body energy balance (51) through the leptin-receptor (Ob-
R).
Ob-R is also present in pancreatic tissue, and it has been
proposed that leptin may increase beta-cell proliferation of
insulin-secreting cell line [163].
Leptin has also been reported to prevent pancreatic
beta-cells from inducible apoptosis, and this may partially
account for islet hypertrophy in obese rodents and patients.
Leptin may exert its antiapoptotic eﬀects on pancreatic beta-
cells. This was associated with a reduction of triglyceride
accumulation, an inhibition of nitric oxide production, and a
restoration of Bcl-2 expression in the face of fatty acid insult.
This may be a possible mechanism for its antiapoptotic eﬀect
[164–166].
In the past, it was reported that leptin acted via the
JAK/STAT and MAPK pathways and has been shown to
increase beta-cell proliferation in cell line studies and foetal
pancreatic tissue [167, 168].
However, recent findings indicate that leptin mainly acts
through the PI3K-AKT signalling pathway in beta-cell pro-
liferation [169–171]. All these results suggest that leptin has
a protective role on beta-cell function. However, the eﬀect of
leptin on apoptosis has been conflicting. In vitro, prolonged
exposure to leptin has been associated with impaired beta-
cell function, and increased rates of apoptosis [172].
Furthermore, in contrast to the observations in rodent
animal, leptin is likely to have a deleterious eﬀect on human
islet function [173]. For instance, it was reported that in
isolated islets frommice, leptin was able to increase cell num-
ber through the suppression of apoptosis [164] meanwhile
in human islets in vitro leptin impairs insulin secretion and
induces apoptosis of beta-cells in the presence of 20mM
glucose via activation of c-JNK [174].
Overall, leptin is likely to exert diverse eﬀects in the re-
gulation of pancreatic beta-cell function and proliferation.
Therefore, further research is still required to clarify its dis-
tinct role in various conditions.
Visfatin. Visfatin is an adipokine secreted by adipose tissue
[175], elevated in T2D [176]. This novel compound can mi-
mic the eﬀects of insulin, by binding insulin-receptor, and
exerts protective eﬀects on pancreatic beta-cells acting via
the PI3K/AKT and MAPK pathways [175]. Through these
pathways, visfatin would appear to have the potential to
regulate plasma glucose levels, as well as beneficial eﬀects on
beta-cell mass.
Overall, visfatin may have a protective eﬀect on pancre-
atic beta-cell mass, but further research is necessary to clarify
its distinct roles.
Placental Hormones. These hormones (especially placental
lactogen and prolactin) are principally responsible for the
changes in beta-cell mass during pregnancy (reviewed in
[177, 178]). These hormones stimulate beta-cell proliferation
in isolated islets, and beta-cell mass is reduced 26–42% in
receptor deficient mice [179] as described in a later.
Connexin. Beta-cell-cell interactions are mediated by con-
nexins (Cxs). These proteins form the gap junction domains
of cell membranes. Cxs have been shown to aﬀect cell
proliferation and survival in diﬀerent cell types [180–182].
In particular, it was reported that the Cx36 isoform is the
only one expressed in rodent beta-cells [183]. A recent stud-
y performed by Klee et al. [184], using Connexins-inducible/
knockout transgenic mouse models, reported a key role in
beta-cell mass regulation by demonstrating that the native
Cx36 does not alter islet size or insulin content, whereas the
Cx43 isoform increases both parameters, and Cx32 has a
similar eﬀect only when combined with the GH.
Bone Morphogenetic Proteins. As recently reported, there are
some new mediators that are responsible of prolifera-
tion/apoptosis of beta-cells. Bone morphogenetic proteins
(BMPs) are growth factors involved in the pancreas mass
homeostasis both during embryonic development and adult
life [185, 186]. The binding of these molecules, in particular
BMP1 and BMP4, to their specific receptors induce, the
phosphorylation and nuclear translocation of SMADs. In
addition, there were identified diﬀerent target genes able to
regulate diﬀerent transcription factors (ID1, ID2, ID3, ID4)
and proteins involved both in the proliferation and apoptosis
processes (including GK, IRS, E2F, SMAD7/9, HES-1).
This is the reason why BMPs have a double eﬀect, both
proliferative and proapoptotic.
2.2. Signalling Pathways in Beta-Cell Mass Homeostasis. An
ever expanding literature suggests that the above-described
hormonal and nonhormonal factors are able to regulate beta-
cell mass by cell cycle regulatory proteins and a range of
key signalling pathways. Of particular interest in the light of
recent data are mitogenic and apoptotic signalling pathways
regulated by the transcription factor c-Myc [46], down-
stream targets involved in G1/S transition [187–195], and
various relevant pathways, including PI3K-AKT and MAPK.
In particular, the PI3K-AKT pathway is an importantme-
diator of beta-cell mass increase [5, 136, 196]. In fact, PI3K-
AKT is known to play a major role in preventing c-Myc
apoptosis in many cell types [197] and to promote hyper-
trophy, hyperplasia, and neogenesis [5].
Phosphatidylinositol 3-Kinase/AKT Pathway. There are many
signal transduction pathways involved in the regulation of
beta-cell mass, with phosphatidylinositol 3-kinase (PI3K)
and AKT signalling being one of the best defined [198].
This pathway is activated by factors, such as glucose, insulin,
IGFs, and GLP-1 [136, 199], and is able to regulate beta-cell
size, proliferation, and apoptosis. Following ligand-receptor
binding, insulin receptor substrate (IRS) is phosphorylated
and is able to interact with various downstream targets. The
most important target of IRS is PI3K, which in turn can
activate PDK1 (via a secondary messenger) [200], resulting
in the activation of AKT [200, 201]. AKT plays diverse
roles in the beta-cell, including activation of glycogen syn-
thase kinase-3 (GSK3, described later), and phosphorylation
and nuclear exclusion of Forkhead transcription factor O1
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Figure 2: Schematic representation of PI3K/Akt and MAPK signalling. Mechanisms of some growth factors modulate beta-cell replication
through proliferation or apoptosis. These factors on one hand stimulate PI3K, AKT, MAPK, and increase beta-cell proliferation. On the
other hand, stimulate AKT, FOXO1, and other proapoptotic molecules resulting in induction of apoptosis.
(FOXO1) [202], ultimately leading to cell growth/replication
and suppression of apoptosis [191] (described in Figure 2).
This is further evidenced in IRS2 −/− mice, whereby beta-
cell proliferation was achieved by ablation of one allele of
FOXO1 [203].
It was reported that PDX1 transcription is regulated posi-
tively by forkhead transcription factor A2 (FOXA2) but neg-
atively by FOXO1 [204, 205]. In fact, these 2 forkhead tran-
scription factors share common DNA-binding sites in the
Pdx1 promoter, FOXO1 competes with FOXA2 for the same
binding site resulting in the inhibition of Pdx1 transcription
[204]. Moreover, nuclear translocation of FOXO1 excludes
PDX1 from the nucleus, or vice versa [204, 206]. In addition,
constitutively active nuclear FOXO1 has been shown to
inhibit beta-cell proliferation in the face of insulin resistance
[207]. This serves as a second mechanism by which FOXO1
inhibits beta-cell proliferation.
Recently, studies of beta-cells exposed to low nutrition
revealed an additional beneficial role of FOXO1 activation—
beta-cell proliferation without any changes in apoptosis
compared to the control group [208]. Moreover, this study
revealed that PI3K and MAPK signalling pathways are
dampened and that the induction of CyclinD1 expression by
activated FOXO1 in low nutrition is responsible for the
improved proliferation of beta-cells [208].
Various studies using animal models to evaluate the role
of diﬀerent molecules on the PI3K/AKT pathway and beta-
cell mass regulation have been performed.
Both IRS1 and 2 are critical for beta-cell growth and sur-
vival (previously mentioned), and they occupy a key position
between the insulin receptor and downstream signaling
elements. IRS1 −/− knockout mice develop severe insulin re-
sistance [209, 210] and compensate for insulin resistance
by increasing beta-cell mass [211]. Although IRS2 −/− mice
are born with only a slightly reduced beta-cell mass, they
later develop diabetes due to a marked increase in spontan-
eous apoptosis and reduced survival of beta-cells [209]. It,
therefore, appears that IRS2 plays an important role in
maintaining beta-cell homeostasis.
Furthermore, the role of AKT has been studied in beta-
cells using genetically altered mice in which AKT is knocked
out or overexpressed. AKT knockout mice displayed an in-
crease of blood glycaemia and insulin resistance, although
there have been conflicting reports on the eﬀect on compen-
satory beta-cell growth [212]. Overexpressing AKT in trans-
genic mice led to a significant increase in beta-cell mass
[5, 213]. In addition, AKT has been shown to promote beta-
cell survival in vivo [214], suggesting an important role for
AKT in beta-cell mass regulation.
The role of FoxO1 on signal transduction was further evi-
denced in diﬀerent mouse models. It was demonstrated that
constitutively active form of FoxO1 protects β cells from
oxidative-stress-induced damage [197], and using another
mouse model, it was demonstrated that deletion of one allele
of FoxO1 resulted in a marked increase in the number, but
not the size [209].
The role of PDX1 in beta-cell biology has been predom-
inately examined in knockout studies. However, inactivating
mutations in one Pdx-1 allele have yielded conflicting results,
although a “critical” level of PDX-1 is thought to be required
in order to maintain beta-cell mass that [215, 216].
GSK3. Glycogen synthase kinase-3 (GSK3), a constitutively
active serine/threonine kinase, was the first substrate shown
to be phosphorylated by AKT (8).
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Mice overexpressing a constitutively active form of GSK3
in beta-cells display reduced levels of PDX-1 protein [217]. In
vitro studies confirmed the role of GSK3 in regulating PDX-1
protein stability, for example, in MIN6 cells, GSK3 has been
shown to phosphorylate PDX-1 leading to its proteasomal
degradation. These results highlighted a new mechanism,
whereby signalling through the PI3K/AKT/GSK3 pathway
regulates beta-cell growth [217]. In addition to the mod-
ulation of PDX-1 stability, GSK3 can also regulate beta
cell proliferation through phosphorylation and degradation
of cell cycle proteins, such as cyclin D1 and/or p27 [218,
219]. Other targets of GSK3 include numerous transcription
factors involved in the cell cycle including c-Myc and c-Jun
[220]. Therefore, in response to diﬀerent growth factors,
AKT prevents GSK3 phosphorylation of cyclin D, thereby
promoting cell cycle progression and subsequentmitogenesis
(Figure 2).
Mitogen-Activated Protein-Kinase (MAPK) Pathway. IRS can
activate the RAF-MEK-ERK pathway (aka the mitogen-acti-
vated protein-kinase (MAPK) pathway, Figure 2) which plays
a crucial role in development, cellular diﬀerentiation, and
mitogenesis [221]. Firstly, IRS engages the adaptor molecule
growth factor receptor-bound protein-2 (Grb2) via its SH2
domain [222, 223]. In turn, Grb2 binds to the murine Son-
Of-Sevenless-1 protein (mSOS), which is able to activate RAS
protein [222, 223]. It then, associates with RAF serine kinase
[224], which subsequently phosphorylates mitogen activated
protein kinase-kinase (MEK) resulting in the activation of
ERK/MAPK [223]. Activated ERK/MAPK can then activate
other protein kinases or migrate to the nucleus to activate
transcription factors, such as c-JUN, c-MYC and c-FOS,
important in the cell cycle [225].
However, the RAS/MAPK pathway can also be activated
independently of IRS via direct binding of Grb2 to the
receptor’s SH2 domain [222, 223].
Janus Kinase/Signal Transducers and Activators of Transcrip-
tion Pathway. Another important pathway in beta-cell bio-
logy is the JAK/STAT pathway. Both growth hormone (GH)
and prolactin have been shown to mediate their eﬀects via
this pathway [226, 227]. Once activated, Janus kinases (JAKs)
are able to phosphorylate signal transducers and activators
of transcriptions (STATs) which enter the nucleus to regulate
transcription of target genes. In particular, JAK2 and STAT-5
have been shown to regulate beta-cell growth and survival
[226–228], as well as to reduce apoptosis [229]. More re-
cently, it was recognized that the JAK/STAT pathway is re-
gulated by Suppressors of cytokine signaling (SOCS). These
suppressor proteins inhibit STAT phosphorylation by bind-
ing to phosphorylated JAKs, or compete with STATs for
phosphotyrosine binding sites on cytokine receptors. Fur-
thermore, SOCs facilitate the degradation of JAKs [230]
(Figure 3). Its eﬀects have resulted in reduced beta-cell pro-
liferation in a sex-dependent manner [231].
c-Myc. The cellular proto-oncogene, c-Myc, encodes the
protein c-Myc whose key biological function is to promote
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Figure 3: Schematic representation of JAK/STAT signalling. Mech-
anisms through prolactin and growth hormone modulate beta-cell
proliferation. These hormones via prolactin receptor activate JAK,
which is able to phosphorylate STAT. After phosphorylation, two
molecules of STAT bind together and translocate into the nuclei
where elicit their transcriptional function.
cell cycle progression. However, this enigmatic protein ap-
pears to be a key player in various other biological processes,
such as diﬀerentiation, cell death, and angiogenesis.
Recent studies by several laboratories, including our own,
support the notion that c-Myc may have a central role in the
regulation of beta-cell mass required for replication (during
the G1/S transition), cell growth, and apoptosis [227].
It is likely that blood glucose levels influence the re-
gulation and expression of c-Myc in beta-cells. In fact, it was
observed that expression of c-Myc was stimulated by high
glucose in a Ca2+-dependent manner and also by cAMP
[232]. High glucose also increases c-Myc mRNA levels in rat
islets in vitro [233]. Therefore, taken together, these studies
support the opinion that high blood glucose levels may
activate beta-cell replication through c-Myc expression.
Besides, the actual mechanism by which hyperglycaemia
activates c-Myc is fully clear. It is known that cell signalling
of c-Myc pass through cyclin E-CDK2 activity early in the G1
phase of the cell cycle, an essential event in c-Myc-induced
G1-S progression [234, 235].
In particular, it is well known that CCND2 (which
encodes cyclin D2) and CDK4 are direct target genes of c-
MYC [236, 237]. Expression of CCND2 and CDK4 leads to
sequestration of p27, the CDK inhibitor, in cyclin D2–CDK4
complexes [236]. The subsequent degradation of p27 has
been shown to involve two other c-MYC target genes, CUL-1
and CKS [237]. By preventing the binding of p27 to cyclin
E-CDK2 complexes, c-MYC allows inhibitor-free cyclin E-
CDK2 complexes to become accessible to phosphorylation
by cyclin activating kinase (CAK). Increased CDK2 and
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CDK4 activities would result in Rb hyperphosphorylation
and subsequent release of E2F from Rb.
However, the final result of c-Myc activation on beta-
cell is peculiar and diﬀers in various tissues. For example,
in contrast of skin, the predominant eﬀect of activating
c-MYC in pancreatic beta-cells of adult transgenic mice
(cMYCERTAM) is apoptosis and not proliferation, resulting
in development of diabetes [46, 238].
However, concerning cell signalling mechanism involved
in cMYC-induced apoptosis, D cyclins do not appear to be
required for c-MYC-induced apoptosis in vitro [239], indi-
cating that these two major functions of c-MYC (prolifera-
tion and apoptosis) may involve, at least in part, distinct sets
of downstream mediators.
Calcineurin/Nuclear Factor of Activated T-Cells. More
recently a new important pathway able to regulate beta-cell
mass and function has been identified. The key components
of this pathway are Ca2+/calmodulin-dependent protein
phosphatase 2-b (or calcineurin-b) and nuclear factor of
activated T cells (NFAT).
In beta-cells calcineurin is activated by an increase of
cytosolic Ca2+, once activated, it can dephosphorylate NFAT
transcription factors, which translocate into the nucleus
where bind to consensus NFAT binding elements on specific
gene promoters resulting in the activation of gene tran-
scription [240]. On the contrary, some specific NFAT kinase
can phosphorylate NFAT proteins and then inactivate and
exporting them from nucleus.
In particular, it was reported in transgenic NFAT acti-
vated mice that NFAT in beta-cells can induce proliferation
activating transcription of genes coding for cyclin D1, cyclin
D2, and CDK4 [159].
More recently, another possible way to regulate the beta-
cell mass has been reported. In fact, it was observed that cal-
cineurin/NFAT pathway is implicated in the glucose regula-
tion of IRS-2 gene expression. In particular, NFAT activated
can bind to IRS-2 promoter enhancing its transcription and
it was prevented by specific inhibition of NFAT [241]. This
positive eﬀect on beta-cell survival observed was also pre-
viously described [242]. Unfortunately, until now, the me-
chanisms involved in the regulation of beta-cell cycle by
calcineurin are partially understood.
The important role of calcineurin/NFAT on beta-cell
proliferation was highlighted using diﬀerent transgenicmod-
els. Using mice with beta-cell-specific deletion of the Cal-
cineurin phosphatase regulatory subunit, Calcineurin b1
(Cnb1), has shown a reduction of beta-cell function, prolif-
eration and mass, and it coincided with reduced expression
of normal regulators of beta-cell proliferation. Similarly,
long-term activation of calcineurin induces impaired glucose
tolerance by alterations in beta-cell mass, and the activation
of calcineurin signalling negatively aﬀects proliferation and
survival of beta-cells [243].
On the contrary, in normal adult beta-cells, conditional
NFAT activation has shown to promote expression of cell-
cycle regulators resulting in an increase of beta-cell prolifer-
ation and mass, resulting in hyperinsulinaemia [159].
2.3. Cell Cycle/Molecular Pathways of Beta-Cell Proliferation.
The critical point in the beta-cell cycle seems to be the G1S
“checkpoint.” At this point, the cell is committed to DNA
replication, and it is regulated by the retinoblastoma protein
(Rb). Rb is critical because it has the ability to stall the
cell cycle. Rb itself is inactivated by a group of serine threo
nine protein kinases, the cyclin-dependant kinases (CDKs)
including CDK4/6 and CDK2, which in turn are negatively
regulated by cyclin-dependent kinase inhibitors (CDKIs).
(i) Rb is a member of a family of pocket proteins which
is able to block G1S transition by binding to E2F tran-
scriptional activator proteins. When liberated from
Rb, E2F transcription factor elicits its activity in
controlling the transition from G1 to S phase.
Mice deleted for E2F-1 display defective pancreatic
growth and islet dysfunction [187]. In E2F-1 and
E2F-2 double knockout mice, both exocrine and en-
docrine glands had atrophied by 3 months of age, a
feature not seen in single knockouts at the same time
point. Diabetes subsequently followed, along with an
increased rate of apoptosis [182].
(ii) The cyclin-dependent kinase CDK4 and 6 are activated
by Cyclin D (in particular, D1 and D2) whereas
CDK2 is activated by Cyclin E. Both Cyclins D1 and
D2 are essential for normal postnatal islet growth. In
adult islets, global deletion of cyclin D2 fails to stim-
ulate adequate compensatory upregulation of cyclin
D1 within islets and drastically damages postnatal
beta-cell proliferation, islet mass, and decreases glu-
cose tolerance [7, 189]. The importance of cyclin
D1 has been highlighted using transgenic mice that
overexpress cyclin D1. In this animal model, an in-
crease in both beta-cell mass and proliferation was
shown [190].
CDK4 has also been shown to be a key regulator of
beta-cell cycle [244]. Knockout studies have shown
a very specific phenotype, with beta-cell hypoplasia
and severe diabetes [191, 194, 245], whilst studies
using an activating mutation in CDK4, rendering it
resistant to p16, have resulted in pancreatic hyper-
plasia, which demonstrated normal physiology [191,
192]. Other studies have shown up to a three-fold
increase in beta-cell proliferation with CDK4 overex-
pression [191, 193].
(iii) The CDKs are inhibited by two groups of CDK in-
hibitors (CDKIs) which are also expressed in islets,
INK4 proteins (p16, p15, p18, p19 inhibit CDK 4 and
CDK6), and CIP/KIP proteins (p21, p27 and p57).
Whilst INK4 family proteins promote cell cycle arrest,
p21 and p27 are integrated into the cyclin D/Cdk4
complex that is able to arrest cell cycle progression
through dephosphorylation of Rb protein [246], on
the other hand, they are able to inhibit cyclin E/A
CDK2 complex resulting in a block of phosphoryla-
tion of Rb protein [247].
Various studies have looked at the eﬀects of CDKIs
on islets. In p21−/− mice, islets were phenotypically
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and metabolically comparable to their wildtype
counterparts, possibly due to upregulation of p57,
whereas loss of function of p57 has been associated
with hyperinsulinaemia at infancy [248]. Actively in-
hibiting the eﬀect of p18, using knockout mice re-
sulted in beta-cell hyperplasia of up to 40% that
appears to be CDK4 dependent [245].
In contrast, p27 has been shown to partially reverse
the islet phenotype independent of CDK4. Over-
expression of p27 in beta-cells of transgenic mice
impairs beta-cell proliferation, resulting in decreased
beta-cell mass and diabetes [195]. Furthermore,
p27−/− mice increases beta-cell proliferation dou-
bling their beta-cell mass at birth, and this expansion
was accompanied by increased insulin secretion
[249].
3. Role of MicroRNAs on the Beta-Cell
Mass Regulation
MicroRNAs (miRNAs) are small 19–23 nucleotide noncod-
ing RNA molecules that act as posttranscriptional regulators
of diﬀerent genes involved in various cellular processes, such
as apoptosis, diﬀerentiation, and proliferation. This regula-
tion pass through Generally, miRNAs can regulate protein
synthesis either by repressing translation and/or by degrada-
tion through deadenylation of mRNA targets [250, 251].
The role of miRNAs in beta-cell mass regulation is not
yet fully understood. The most studied miRNA in this con-
test is miR-375. It was reported that its overexpression atten-
uates proliferation of beta-cells and glucose-induced insulin
secretion [16–18]. Indeed, ectopic expression of miR-375
in diabetic pancreatic beta-cells results in increased suscep-
tibility to fatty acid induced apoptosis [16]. Moreover, it was
reported that in ob/ob mice in which miR-375 was deleted,
they develop a marked decrease in beta-cell mass, which re-
sults in a severe insulin-deficient diabetes not found in ob/ob
mice [15]. Therefore, it is becoming clear that miR-375
targets a suit of genes that negatively regulate cell growth and
proliferation and that aberrant loss of this miRNA leads to
dramatic reduction of beta-cell mass [15].
Furthermore, it was reported that overexpressions of
both miR-34a and miR-146a are involved in programmed
cell death, in particular, in apoptotic processes. In contrast,
reducing miR-34a or miR-146a levels did not aﬀect cell
survival.
In fact, prolonged beta-cell exposure to palmitate (FFA)
and proinflammatory cytokines changes/increases the ex-
pression of miR-34a and miR-146a, and treatment with anti-
miR34a or anti-miR148 diminished the number of death
cells in the presence of apoptotic stimulus.
The eﬀect on the regulation of apoptosis may be due to
the capacity of miR-34 to control the expression of the anti-
apoptotic protein Bcl2 [252], meanwhile miR-146a may con-
trol the apoptotic process through the regulation of the NF-
kB pathway [253].
4. Beta-Cell Mass Plasticity
In addition to maintaining beta-cell mass under normal cir-
cumstances, as just discussed, an organism must also be able
to alter its beta-cell mass in accordance with insulin’s re-
quirements. In particular conditions, such as pregnancy and
obesity, beta-cell mass enlargement is observed [2]. However,
when compensatory beta-cell mass expansion is inadequate,
gestational diabetes in the case of pregnancy and T2D in the
case of obesity are the results.
Although the majority of humans do not become dia-
betic in these circumstances, a significant part of the po-
pulation is predisposed to beta-cell failure, for currently un-
known reasons. The precise mechanism of beta-cell mass
maintenance and expansion, that is, proliferation, neogen-
esis, or increase in size, has been elucidated only in part
[178, 254, 255].
4.1. Reversible Beta-Cell Mass Expansion during Pregnancy.
Diﬀerent studies in rodents found a two- to five-fold increase
in beta-cell mass during gestation [255, 256] and demon-
strated an involvement of both beta-cell hypertrophy [178,
256, 257] and proliferation [256, 257]. Van Assche et al. [254]
have reported that in humans during pregnancy the beta-
cell mass increased 2.4-fold compared with nonpregnant
women. Unfortunately, human data are limited to few studies
using a small number of subjects. Butler et al. [258] have
reported an approximately 1.4-fold increase in beta-cell mass
using 18 women. In contrast to rodents, beta-cell mass ex-
pansion in humans was achieved by the formation of new
islets or islet neogenesis [258].
The main stimuli for beta-cell proliferation during preg-
nancy are placental lactogen (PL), prolactin (PRL), growth
hormone (GH) [178, 259], and serotonin [260]. Postpartum,
in rodents, beta-cell mass returns to normal levels within 10
days through increased beta-cell apoptosis, decreased beta-
cell proliferation, and reduced beta-cell size [255].
Placental Lactogen. Placental lactogen (PL) hormone has
been implicated as the primary factor responsible for the
enhanced islet mass and function that occur during preg-
nancy [178, 259]. PL interacts with receptors in the PRL/GH
receptor family, stimulating the JAK-2/STAT-5 intracellular
signalling pathway [261, 262].
Prior studies performed in vitro and over the short term
suggested that PL is a more powerful islet mitogen than GH
or PRL [178, 263]. These data were confirmed in in vivo stud-
ies using transgenic mice expressing mouse PL-1 under the
control of the rat insulin promoter (RIP-mPL1) [259, 264].
The expansion of beta-cell mass in RIP-mPL1 was attributed
principally to a two-fold increase in beta-cell proliferation
and a 20% increase in beta-cell size (hypertrophy). Inter-
estingly, islet number was not significantly increased when
compared to wild-type mice [259]. These findings were sup-
ported by a PL receptor knockout study, which showed a sig-
nificant reduction in beta-cell mass [265]. Therefore, PL
could oﬀer a novel therapeutic target to treat diabetes.
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Prolactin. Prolactin (PRL), a hormone, acts through its
specific receptor, prolactin-receptor (PRLR) to induce beta-
cell proliferation in vitro [263]. Targeted deletion of the
PRLR reduces beta-cell mass and mildly impairs insulin
secretion [265]. The pivotal role of the PRLR for beta-
cell adaptation during pregnancy was demonstrated using
pregnantmice heterozygous for the PRLR null mutant. These
mice exhibited reduced beta-cell proliferation, and impaired
glucose tolerance [266]. It has been extensively demonstrated
in diﬀerent in vitro studies that PRL binding to PRLR is
able to activate diﬀerent signaling pathways such as STAT5,
MAPK, and IRS/PI3K resulting in enhancing beta-cell mass
during pregnancy [267–269]. It is currently unclear whether
PRL and/or PL stimulate these pathways in vivo.
Menin. More recently, menin (a tumour suppressor encoded
by the Men1 gene) has been linked to the regulation of
beta-cell proliferation during pregnancy [157]. Expression
of menin, p18, and p27 are reduced during pregnancy in
maternal islets, thus leading to islet mass expansion to meet
the increased metabolic demand. After birth, menin returns
to normal. Interestingly, menin is regulated by prolactin
[157], supporting menin as an important mediator of beta-
cell proliferation during pregnancy. It has also been proposed
that, during pregnancy, activation of JAK2 and AKT, in
response to prolactin, leads to increased p21 expression,
whereas menin and p18 expression are suppressed. It is well
known that AKT and p21 induce beta-cell proliferation,
meanwhile the downregulation of menin and p18 allows for
enhanced beta-cell proliferation [270].
Serotonin. A recent study by Kim et al. [260] shows that
beta-cells, like serotoninergic neurons, are able to synthesize,
store, and secrete serotonin (5-HT) as well as express the spe-
cific serotonin receptors (5-HTR2B and 5-HTR1D). These
authors reported that, in pregnantmice, 5-HTR2Bexpression
increased significantly during midgestation (day 6 to 16)
and normalized at the end of gestation, whereas 5-HTR1D
expression increased at the end of gestation (day 17) and
postpartum. Notably, increased 5-HTR2Bexpression closely
correlated with the period of increased beta-cell prolifera-
tion, and increased 5-HTR1Dexpression correlated with the
cessation of beta-cell proliferation and regression of beta-
cell mass. Moreover, it was reported that in pregnant mice
stimulation with high concentrations of prolactin induces a
strong increase in the serotonin expression compared with
nonpregnant control mice.
These results suggest that during pregnancy lactogenic
signalling induces serotonin expression and synthesis in
islets able to stimulate beta-cell proliferation through the
5-HTR2B pathway. Shortly before parturition, expression
of 5-HTR2B decreases and 5-HTR1D expression increases,
resulting in the reduction of beta-cell proliferation and beta-
cell mass. In this way, beta-cell mass returns rapidly to
prepregnancy levels.
4.2. Compensation for Body Mass. Excessive increase in
body weight leads to obesity. Obesity is linked/correlated
with insulin resistance and associated with compensatory
physiological response at the level of beta-cell mass increase.
As previously described, when compensatory beta-cell mass
expansion is inadequate, T2D in the case of obesity is
consequential.
Diet-induced obesity results in insulin resistance and
beta-cell mass expansion in humans and mice. In nondi-
abetic animal models of obesity, for example, the C57Bl/6
mouse strain which is notoriously susceptible to these eﬀects,
there is a 2.2-fold increase in beta-cell mass and proliferation
after 4 months of a high-fat diet versus a control diet [271].
Meanwhile, in the Zucker diabetic fatty (ZDF) fa/fa rat, beta-
cell mass increased four folds compared with lean controls
[79]. There is also evidence for increased beta-cell mass in
nondiabetic obese humans [51].
However, these mice eventually become diabetic and lose
their beta-cell mass due to increased beta-cell apoptosis and
reduced beta-cell proliferation.
In genetic models of obesity and insulin resistance, there
is a compensatory expansion of beta-cell mass. For example,
in mice lacking a functional leptin receptor (db/db mice),
beta-cell mass exhibits two-fold beta-cell mass increase
[115]. The Zucker rat (fa/fa) also has a homozygous mu-
tation in the gene encoding the leptin receptor. ZDF rats
exhibit increased beta-cell mass and increased beta-cell pro-
liferation prior to the onset of diabetes, but increased beta-
cell apoptosis prevents them from adequately expanding
their beta-cell mass after the onset of diabetes, despite
continued high rates of beta-cell proliferation [79]. This
phenotype contrasts with that observed in nondiabetic
Zucker fatty (ZF) rats, which possess the same mutation as
ZDF rats and also become obese and insulin resistant but
do not develop diabetes due to suﬃcient beta-cell mass ex-
pansion through increased beta-cell proliferation, neogene-
sis, and hypertrophy [79].
5. Conclusions
On the basis of available research findings that we have dis-
cussed above, we can propose that (i) postnatal beta-cell mass
sizes in response to changing metabolic demands, (ii) is
carried out by an interaction of beta-cell replication (prolife-
ration and/or neogenesis) and apoptosis, and (iii) this pro-
cess is regulated by diﬀerent growth factors/nutrients that
interact between them.
Actually, our present knowledge to the understanding of
proliferation, neogenesis, and apoptosis is still incomplete.
The balance between apoptosis and replication seems to
be pivotal in a right beta-cell mass maintenance. Failure in
this balance results in beta-cell dysfunction and consequently
diabetes onset. Because of the worldwide diﬀusion of this
pathology, new therapies able to restore the original beta-cell
mass and its functionality are under continuous develop-
ment. Islet transplantation is already under clinical investiga-
tion but for the foreseeable future it will be very restricted in
application due to the limited supplies of human cadaveric
islets for transplantation. As a result, there is intense in-
terest in developing other sources of new beta-cells and
identification of new molecules able to restore beta-cell mass
in diabetics.
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